We are live on ! Find out more
AVAI

Atlas Venture Associates IX Portfolio holdings

AUM $11.8M
1-Year Est. Return 58.35%
This Fund
S&P 500
This Quarter Est. Return
+3%
1 Year Est. Return
-58.35%
3 Year Est. Return
-89.8%
5 Year Est. Return
-87.69%
10 Year Est. Return
–
AUM
$595M
AUM Growth
-$35.8M
Cap. Flow
-$42.9M
Cap. Flow %
-7.21%
Top 10 Hldgs %
100%
Holding
7
New
–
Increased
1
Reduced
2
Closed
–

Top Buys

Rank Stock Value
1
COGT icon
Cogent Biosciences
COGT
+$6.12K

Top Sells

Rank Stock Value
1
NTLA icon
Intellia Therapeutics
NTLA
+$33.7M
2
FIRY
Firy Inc
FIRY
+$9.24M

Sector Composition

Rank Sector Weight
1 Communication Services 74.77%
2 Healthcare 25.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FIRY
1
Firy Inc
FIRY
$163M
$437M 73.46%
1,148,146
-16,074
-1% -$9.24M
NTLA icon
2
Intellia Therapeutics
NTLA
$1.67B
$89.4M 15.01%
1,113,376
-501,945
-31% -$33.7M
SURF
3
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$23M 3.86%
2,945,453
– –
SPRO icon
4
Spero Therapeutics
SPRO
$73M
$20.3M 3.41%
1,376,968
– –
SYBX
5
DELISTED
Synlogic
SYBX
$9.49M 1.6%
176,798
– –
COGT icon
6
Cogent Biosciences
COGT
$7.24B
$8.05M 1.35%
916,832
+636
+0.1% +$6.12K
SNAP icon
7
Snap
SNAP
$9.01B
$7.85M 1.32%
150,160
– –

Similar funds

EEPIS
Evolution Equity Partners II SARL Luxembourg $11.8M AUM 63.6% 1-Year Est. Return
LM
Lockheed Martin Bethesda, Maryland $12.1M AUM 46.13% 1-Year Est. Return
HMP9
Highland Management Partners 9 Cambridge, Massachusetts $12.6M AUM 85.13% 1-Year Est. Return
TCSAM
Tyrus Capital S.A.M. Monaco $10.5M AUM 4.88% 1-Year Est. Return
AEM
ACON Equity Management Washington, District of Columbia $13.8M AUM 62.17% 1-Year Est. Return
PT
Palantir Technologies Denver, Colorado $9.72M AUM 6.46% 1-Year Est. Return
AR
Acacia Research New York $14.1M AUM 50.98% 1-Year Est. Return
MM
Malka Meyer $8.77M AUM 64.77% 1-Year Est. Return

Atlas Venture Associates IX's Q1 2021 Portfolio in Review

As of Q1 2021, Atlas Venture Associates IX held 7 positions worth $595M, down 5.7% from $631M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Atlas Venture Associates IX withdrew a net $42.9M in Q1 2021, reducing 2 holdings. Its largest reduction was Intellia Therapeutics, cutting an estimated $33.7M.

By sector, the portfolio is most concentrated in Communication Services at 75% of assets, down from 75% a quarter earlier, followed by Healthcare.

Against the trend, Atlas Venture Associates IX added an estimated $6.12K to Cogent Biosciences.

  • Atlas Venture Associates IX added most to Cogent Biosciences in Q1 2021, an estimated $6.12K increase.
  • Atlas Venture Associates IX's biggest Q1 2021 reduction was Intellia Therapeutics, cutting an estimated $33.7M.
  • Atlas Venture Associates IX's ten largest holdings make up 100% of its $595M portfolio in Q1 2021.
  • Atlas Venture Associates IX opened 0 new positions and closed 0 in Q1 2021.
  • Atlas Venture Associates IX's portfolio value fell 5.7% quarter-over-quarter to $595M.

Based on Atlas Venture Associates IX's 13F filing for Q1 2021, filed 14 May 2021.